Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million
Rocket Pharmaceuticals closed the sale of its Rare Pediatric Disease Priority Review Voucher for gross proceeds of $180 million. The voucher was granted by the FDA in March 2026 following the approval of KRESLADI, the company’s gene therapy for severe leukocyte adhesion deficiency-I.
Key figures
- Deal Value Usd
- 180000000
- Cash prior
- 144400000
- Cash pro forma
- 322600000
- Runway extension
- Q2 2028
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.